Command Palette

Search for a command to run...

Clinical Trials · NCT04823208

A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)

CompletedPhase 1Retatrutide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
64
Start date
May 2021
Locations
4 sites, Japan
Primary endpoint
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
View Retatrutide compound reference